BMP-2 Peptide for Researchers: Sequences, QC, and Dosing

For laboratory and research use only. Not for human consumption.

BMP-2 (Bone Morphogenetic Protein 2) is a signaling protein studied in the research literature primarily in the context of osteoblast differentiation and bone-tissue formation, a regulatory process examined extensively in cell-culture and animal-model systems. This overview summarizes what published research describes about the compound's structure, proposed receptor mechanism, and preclinical findings, and clarifies its current research-use status.

Key Facts

BMP-2 is a disulfide-linked homodimer belonging to the TGF-beta superfamily, with each monomer stabilized by a cystine-knot fold formed from three intrachain disulfide bonds.
Research literature describes its mechanism as binding to BMPR-IA/BMPR-IB (type I) and BMPR-II (type II) receptors, activating the canonical Smad1/5/8 signaling pathway.
Downstream Smad signaling regulates transcription of osteogenic marker genes including Runx2, Osterix (Sp7), alkaline phosphatase, and type I collagen in model systems.
Preclinical findings come primarily from rodent ectopic-implantation and critical-size bone-defect models, typically using a carrier scaffold such as an absorbable collagen sponge, not human clinical trials.
A specific, carrier-formulated recombinant human BMP-2 device product has narrow FDA-approved clinical indications, but this is a distinct, tightly regulated product separate from unformulated BMP-2 sold for laboratory research, which carries no such approval.

What Is BMP-2?

BMP-2 belongs to a family of signaling proteins originally identified through research into demineralized bone matrix extracts that, when implanted into animal tissue, were observed to induce new bone formation at the implantation site. That line of investigation eventually led to the molecular cloning and recombinant production of individual bone morphogenetic protein family members, including BMP-2, as distinct TGF-beta superfamily ligands. Structurally, the mature BMP-2 protein is a disulfide-linked homodimer: each monomer adopts a cystine-knot fold, in which three intrachain disulfide bonds create a knotted core, and the two monomers are joined by an additional interchain disulfide bond to form the covalently linked dimer that constitutes the biologically active ligand. This architecture is characteristic of the broader TGF-beta superfamily, which also includes myostatin, activin, and the other BMP family members, some of which BMP-2 can also form heterodimers with in structural studies.

Proposed Mechanism: BMPR Receptor Complexes and Smad Signaling

Research literature describes BMP-2 as signaling through a heteromeric receptor complex composed of type I receptors, BMPR-IA (ALK3) or BMPR-IB (ALK6), and the type II receptor, BMPR-II, all of which are transmembrane serine/threonine kinases. BMP-2 binding brings these receptor types together, allowing the constitutively active kinase domain of BMPR-II to transphosphorylate the GS domain of BMPR-I. The activated type I receptor then phosphorylates the receptor-regulated Smad proteins Smad1, Smad5, and Smad8, which dissociate from the receptor complex, bind the common mediator Smad4, and translocate as a complex into the nucleus, where they regulate transcription of osteogenic target genes such as Runx2 and Osterix in concert with other transcriptional cofactors. Published studies also describe non-canonical signaling downstream of BMP-2 receptor engagement, including activation of p38 MAPK pathways, alongside the canonical Smad route. Extracellular antagonists such as noggin, chordin, and gremlin are described in the literature as binding BMP-2 directly and preventing receptor engagement, a ligand-trap mechanism that research on this signaling axis frequently references when characterizing how BMP-2 activity is naturally regulated in model systems.

What Preclinical and Animal-Model Research Has Measured

The bulk of published research on BMP-2 comes from cell-culture assays and animal-model studies, most commonly in rodents, with BMP-2 typically delivered on a carrier scaffold because the literature describes a carrier as necessary for adequate localized bone formation. These studies have measured outcomes such as:

New bone volume and mineral density in ectopic implantation models, where BMP-2 loaded on a scaffold such as an absorbable collagen sponge or a calcium-phosphate ceramic is placed in a rodent muscle pouch and assessed by micro-CT and histology.
Bone bridging and defect healing in critical-size defect models, including rat calvarial, rat fibular, and rabbit metaphyseal defect models, evaluated through radiographic imaging, micro-CT, and histomorphometry.
Expression of osteogenic marker genes, including Runx2, Osterix/Sp7, alkaline phosphatase, and type I collagen, measured in cell-culture assays using techniques such as quantitative PCR and enzymatic activity assays.
Temporal staging of tissue response in some ectopic-implantation studies, with early vascular ingrowth and a transient cartilage intermediate reported ahead of mineralized bone formation at the implantation site.

These findings are specific to the model systems, carrier materials, and study designs in which they were generated. They describe what researchers observed in those cell and animal models under controlled laboratory conditions, and do not constitute evidence about outcomes in humans.

Research-Use Status

A specific recombinant human BMP-2 product, formulated and applied on an FDA-cleared absorbable collagen sponge carrier, holds regulatory approval as a medical device combination product for a narrowly defined set of orthopedic and spinal fusion indications when administered by a qualified clinician under that product's approved labeling. This clinical-grade, carrier-formulated product is manufactured, packaged, and regulated as a distinct medical device combination product with its own approved indications, dosing regimen, and delivery system.

Unformulated BMP-2 supplied as a research reagent is not that product. It is not FDA-approved as a standalone material, is not accompanied by an approved carrier or delivery system, and is not manufactured, labeled, sold, or intended for human or animal clinical, therapeutic, or supplemental use of any kind. Published clinical literature has also documented adverse-event concerns associated with expanded or off-label surgical use of the approved rhBMP-2 device product, including reports of heterotopic (ectopic) bone formation and localized inflammatory swelling, which prompted regulatory safety communications regarding certain off-label applications. This history underscores why research-grade BMP-2 should be handled strictly according to laboratory protocols by qualified researchers, with the identity and purity of each lot verified against its Certificate of Analysis before use in an experiment, and never applied outside a controlled research setting.

Related Bone and Tissue-Regeneration Research Peptide Overviews

BMP-2 is studied alongside other growth-factor and TGF-beta superfamily research compounds that engage related receptor biology. For a look at a related compound within the broader activin receptor signaling family, see our ACE-031 research overview, which covers an activin receptor type IIB fusion protein studied through a comparable receptor-engagement framework. Researchers focused on tissue-repair research more broadly may also find our BPC-157 tissue-healing research overview useful as a comparison point for a structurally unrelated peptide studied in adjacent tissue-regeneration model systems.

Before beginning any laboratory work with BMP-2, reviewing batch-specific identity and purity documentation is an important first step; our testing and COA transparency page outlines how we verify the research materials we supply. For calculating a working concentration from a reconstituted vial ahead of an assay, our reconstitution calculator is available as a reference tool.

Frequently Asked Questions

What is BMP-2?

BMP-2 (Bone Morphogenetic Protein 2) is a signaling protein belonging to the transforming growth factor-beta (TGF-beta) superfamily, structurally characterized as a disulfide-linked homodimer with a cystine-knot fold in each monomer, and it is studied in the research literature primarily for its role in osteoblast differentiation and bone-tissue formation in cell-culture and animal-model systems.

What mechanism does research literature describe for BMP-2 signaling?

Published studies describe BMP-2 as binding to type I receptors (BMPR-IA and BMPR-IB) and the type II receptor (BMPR-II) on the cell surface, forming a receptor complex in which the constitutively active BMPR-II transphosphorylates BMPR-I; activated BMPR-I then phosphorylates the receptor-regulated Smad1/5/8 proteins, which associate with Smad4 and translocate to the nucleus to regulate transcription of osteogenic genes such as Runx2 and Osterix.

What have preclinical and animal-model studies measured for BMP-2?

Animal-model and cell-culture studies referenced in the literature have measured outcomes such as new bone volume and density by micro-CT, histological bone-formation scoring, alkaline phosphatase activity, and expression of osteogenic marker genes, typically using rodent ectopic implantation models or critical-size bone-defect models in which BMP-2 is delivered on a carrier scaffold such as an absorbable collagen sponge.

Is BMP-2 approved for human or veterinary use?

A specific recombinant human BMP-2 product formulated on an FDA-cleared absorbable collagen sponge carrier has regulatory approval for a narrow set of orthopedic and spinal fusion indications when administered by a qualified clinician as a regulated medical device combination product. This is distinct from unformulated BMP-2 research material, which is not FDA-approved as a standalone product, is not manufactured or labeled for clinical use, and is sold and studied strictly as a laboratory research compound.

How do researchers determine appropriate concentrations for BMP-2 in a laboratory protocol?

Researchers determine working concentrations for a given study protocol based on the experimental design, assay type, and dose figures reported in peer-reviewed literature for comparable model systems, rather than from any generalized recommendation. This process depends on verifying the identity and purity of the specific research lot through its Certificate of Analysis and applying accurate reconstitution and dilution calculations for that lot.